GlaxoSmithKline has entered into an agreement to divest full commercial rights to Wellbutrin XL(R) in the US to BLI for $510 million. Under the terms of the agreement, GlaxoSmithKline would transfer its US New Drug Application (NDA) and license the Wellbutrin XL trademark to Biovail in the US. GSK would retain existing rights to Wellbutrin XL, excluding Canada, for countries outside the US.
|